Irina Rebin

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Career

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Education

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

Additional languages

Awards

JUVE Awards 2023

Featured

Irina's news & insights

View Irina's insights

Click here to find out more

Biotech

Impact of the new Biotech Act on Clinical Trials in the EU

15 April 2026

by Irina Rebin

International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

A European Perspective #1 | The EU’s largest pharmaceutical law reform in over 20 years introduces a new regulatory exclusivity framework, revised orphan drug incentives and an antimicrobial voucher. Strategic exclusivity planning will become essential for pharmaceutical companies.

15 April 2026

Briefing

by Irina Rebin

1 of 9 Insights

Click here to find out more

International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

No claim for damages as a result of participation in clinical drug trials

A European Perspective #1 | GERMANY | The Frankfurt am Main Regional Court confirms: No reduction in the burden of proof (presumption of causality) pursuant to Section 84 (2) of the German Medicines Act (AMG) for IMP (not even by analogy) and no liability on the part of the sponsor in the event of (insufficient) risk information provided by the investigating physician.

1 April 2026

by Irina Rebin

7 of 9 Insights

Click here to find out more